Emergent BioSolutions (EBS) Receivables - Net (2010 - 2026)

Emergent BioSolutions' Receivables - Net history runs 17 years deep, the most recent figure standing at $104.1 million for Q1 2026.

• In Q1 2026, Receivables - Net fell 48.9% year-over-year to $104.1 million; the TTM figure through Mar 2026 stood at $104.1 million (down 48.9% YoY), while the FY2025 annual figure was $84.2 million, down 45.5% from the prior year.
• Receivables - Net was $104.1 million for Q1 2026 at Emergent BioSolutions, up from $84.2 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $290.1 million in Q2 2023 to a low of $79.8 million in Q2 2025.
• Historically, Receivables - Net has averaged $167.4 million across 5 years, with a median of $175.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Receivables - Net jumped 65.77% in 2023, then slumped 59.35% in 2025.
• A 5-year view of Receivables - Net shows it stood at $159.2 million in 2022, then grew by 19.97% to $191.0 million in 2023, then dropped by 19.11% to $154.5 million in 2024, then slumped by 45.5% to $84.2 million in 2025, then gained by 23.63% to $104.1 million in 2026.
• The last three Receivables - Net figures came in at $104.1 million (Q1 2026), $84.2 million (Q4 2025), and $149.5 million (Q3 2025), per Business Quant data.